CD274 and non-small cell lung carcinoma: For advanced NSCLC patients with a PD-L1 TPS >50%, the KEYNOTE-024 trial showed that single-agent Pembrolizumab provided long-term survival benefits, enabling patients to avoid chemotherapy (21).